A union of human and animal health

To inform the future of medicine, Kedi treats disease in cats first.

One Health is the perspective that human, animal, and ecosystem well-being are interdependent.

Cats and dogs share our homes, our habits, and our lifestyle diseases. Similar genetics and environments mean that much of the biology animating those diseases, as well as aging, is shared across species. That’s why new drugs are tested in animals before they reach people.

We reframe this logic to put animal welfare first. Instead of inducing disease, we study it when and where it naturally occurs: in our pets. What we learn developing real therapies for real cats can reshape the industry for the benefit of all species.

At Kedi, One Health means recognizing that truly innovative drug R&D should ultimately sustain more lives than it takes.

KEDI’S ONE HEALTH VISION

Veterinary medicine at the center of drug discovery

Kedi and human drug development cycles Two concentric cycles. The outer, teal cycle is human drug development: discovery, cat data in the place of animal testing, human trials and approved medicines. The inner, purple cycle is Kedi: vet drug discovery, pet trials, cat medicines and cat data. The two cycles meet at cat data; vet drug discovery and discovery are highlighted. When animated, the human pipeline runs first: from discovery and animal testing it stalls once before human trials (poor translation) and once before approved medicines, and does not close. Approved medicines and cat data then feed vet drug discovery, and Kedi's cycle runs through pet trials and cat medicines to cat data, while the human cycle is greyed out. The Kedi cycle then drops until cat data takes animal testing's place. A last run starts at discovery alone and reaches cat data, where Kedi's cycle joins and turns alongside; this time the human cycle closes, from approved medicines back to discovery, as Kedi's cycle comes round to cat data. HUMAN DRUG DEVELOPMENT POOR TRANSLATION Vet drug discovery Pet trials Cat medicines Cat data Discovery Animal testing Human trials Approved medicines

OUR PROPOSAL

1. Treat pets as patients

Pets share many of our chronic diseases and too few of our advanced therapies. Many conditions are still managed rather than treated. We develop fully feline medicines from mechanisms proven in human medicine, studied in veterinary trials with monitoring and consent.

2. Bridge the translation gap

Lab models with cells or rodents aren't real disease, and can't predict a patient population's drug responses. We study naturally occurring animal diseases in cats living with them at home and will enroll them in our drug trials to obtain answers from real patients, with fewer resources and less suffering.

3. Assess new mechanisms

Many promising mechanisms have no approved drugs, and good biologic design is still largely trial and error. With every program at Kedi, we gather information to identify and test hypotheses about drug mechanisms and design. Our goal is to accelerate patient impact, for pets and for people.

Focus areas

Cancer

Mutations and genomic aberrations that underlie cancer show many similarities across cat, dog and human tumors. In particular, feline oral squamous cell carcinoma and mammary tumors resemble human head and neck cancers, and breast cancers, respectively. Because these cancers arise naturally, veterinary clinical trials can be more informative for new medicines than rodent studies. Our drug candidates aim to offer new hope for cats with cancers and allow innovative, ethical animal studies to discover new frontiers in oncology.

Allergy and itch

Research shows that cats, as always, do their own unique thing when it comes to the immune system. While allergies and skin diseases manifest differently across humans and cats, clinical experience with drugs suggests that similar therapeutic mechanisms hold promise. We've built a research program to better understand the molecular pathology of feline dermatitis and compare it to human and dog data. Our approach revealed intriguing data and we're developing novel therapeutics that can answer important open questions in immunology.

Obesity and diabetes

Obesity and diabetes are common problems that humans share with their companion animals and, in each case, are associated with poor health outcomes. The revolutionary GLP-1 medicines are now being explored for pets. We study the feline incretin system from the molecular to the clinical level to develop a drug tailored to cats. Our candidates are engineered for very favorable safety profiles with minimal side effects for cats. In the process, we obtain key insights into peptide therapeutics and improve them.

Kidney diseases

There are distinct subtypes of kidney disease with each subtype showing additional heterogeneity among patients. Underlying causes include slow, chronic fibrosis and autoimmune or inflammatory damage, in cats and humans alike. Our research program includes different antibodies for different feline kidney disease subtypes, and a prospective biomarker to help with the distinction. We're advancing a novel drug mechanism, currently not approved for humans, and aiming to answer key open questions in renal care for both cats and humans.

Pain

Pain is one of medicine's hardest problems; it is both poorly understood and difficult to develop drugs for. Data from lab models of pain rarely translate to successful new medicines. Discovering effective drugs that are safe and non-addictive is even more difficult. Companion animals suffer pain mostly secondary to other diseases, such as joint or dental conditions. We're working with a global network of scientists to leverage veterinary clinical trials and animal data to discover new therapeutic approaches against pain.